arachidonylcyclopropylamide and Anxiety-Disorders

Depression and anxiety disorders are among the most common illnesses and a close relationship between them has been found. Because the psychotropic effects and abuse liability of cannabis prevent its therapeutic application in depression and anxiety states, we decided to investigate the effects of the combination of ineffective doses of cannabinoid CB1 receptor agonist arachidonylcyclopropylamide (ACPA) and β-carbolines on anxiety- and depression-related behaviors in male NMRI mice. Anxiety- and depression-related behaviors were assesses using elevated plus maze (EPM) and forced swim test (FST), respectively. Intraperitoneal administration of ACPA (1 mg/kg) decreased the percentage of time spent in the open-arms (%OAT) and the number of entries to the open-arms (OAE) in the EPM, indicating an anxiogenic-like effect. ACPA also decreased immobility time in the FST compared to the control group, suggesting an antidepressant-like effect. β-carbolines including harmane (5 and 10 mg/kg), norharmane (5 mg/kg) and harmaline (2.5 and 5 mg/kg) produced an anxiogenic-like response, while the highest dose of harmane or harmaline and the middle dose of norharmane induced an antidepressant-like behavior. Furthermore, co-administration of a subthreshold dose of ACPA (0.5 mg/kg) and harmaline (1.25 mg/kg), but not harmane or norharmane (both at the dose of 2.5 mg/kg), caused anxiolytic- and antidepressant-like behaviors and decreased locomotor activity. Our findings suggest a therapeutic potential for combined ineffective doses of ACPA and harmaline on anxiety- and depression-related processes.

Topics: Amygdala; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Anxiety Disorders; Arachidonic Acids; Behavior, Animal; Brain; Cannabinoid Receptor Agonists; Carbolines; Depression; Disease Models, Animal; Harmaline; Male; Maze Learning; Mice; Mice, Inbred Strains; Receptor, Cannabinoid, CB1

The critical role of cannabinoidergic and serotonergic systems of the amygdala in modulation of anxiety-like behaviors and emotional memory has already been demonstrated. The present study aimed to investigate the possible role of the basolateral amygdala (BLA) 5-HT3 and 5-HT4 serotonergic systems upon ACPA (CB1 cannabinoid receptor agonist)-induced anxiolytic-like behaviors and emotional memory impairment using the elevated plus-maze (EPM) test-retest paradigm in male mice.. bilateral guide-cannulae were implanted to allow intra-BLA microinjection of serotonergic agents.. the intraperitoneal injection of ACPA could induce anxiolytic-like behaviors and reduce the emotional memory formation. Intra-BLA injection of M-Chlorophenylbiguanide (M-Chl, a 5-HT3 serotonin receptor agonist) neither altered the anxiety-like behaviors nor the emotional memory formation by itself, while the higher dose of Y-25130 (a 5-HT3 serotonin receptor antagonist) reduced the emotional memory formation and locomotor activity but not the anxiety-like behaviors. Furthermore, injection of a higher dose of RS67333 and RS23597 (as 5-HT4 serotonin receptor agonist and antagonist, respectively) did not alter the anxiety-like behaviors, while reduced the emotional memory formation. In addition, the intra-BLA injection of M-Chl but not Y-25130 and RS67333 restored the ACPA-induced anxiolytic-like behaviors and emotional memory deficit, while a higher dose of RS67333 decreased the locomotor activity. Moreover, the intra-BLA microinjection of RS23597 could restore the ACPA-induced anxiolytic-like behaviors but not the emotional memory deficit.. based on our findings, ACPA seems to induce its anxiolytic-like behaviors and emotional memory formation deficits via activation and deactivation of the BLA 5-HT4 and 5-HT3 serotonin receptors.

Topics: Amygdala; Analysis of Variance; Animals; Anxiety Disorders; Arachidonic Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Maze Learning; Memory Disorders; Mice; Microinjections; Receptor, Cannabinoid, CB1; Receptors, Serotonin, 5-HT3; Receptors, Serotonin, 5-HT4; Serotonin Agents